Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00628498 · ClinicalTrials.gov registry record · Phase 3
Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
A Phase 3 study of Hepatic Veno-Occlusive Disease, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,206
- Enrollment target
- 20
- Study locations
NCT00628498 is a Phase 3 study of Hepatic Veno-Occlusive Disease that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 1,206 participants. The trial reports 20 study locations across 5 states.
The verdict
NCT00628498, a Phase 3 study of Hepatic Veno-Occlusive Disease, has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,206 participants
- Enrollment target
- 20
- Study locations
Study Summary
Single arm, open-label study to provide Defibrotide to patients diagnosed with VOD. Defibrotide is no longer available though the Emergency Use IND mechanism (also known as compassionate use, or single patient named use). This protocol is the only mechanism by which Defibrotide can be made available to patients in the U.S.
Conditions Studied
Interventions
- DRUG Defibrotide
Study Locations (20)
California
- City of Hope Medical Center - Duarte
- The University of California, San Diego - La Jolla
- Loma Linda University - Loma Linda
- Long Beach Memorial Medical Center - Long Beach
- Children's Hospital of Los Angeles - Los Angeles
- Children's Hospital & Research Center Oakland - Oakland
- Children's Hospital of Orange County (CHOC) - Orange
- Sutter Institute for Medical Research - Sacramento
- University of California Davis Health System - Sacramento
- Rady's Children's Hospital - San Diego - San Diego
- University of California San Francisco Medical Center - San Francisco
- Stanford University Medical Center - Stanford
Arizona
- Phoenix Children's Hospital - Phoenix
- Mayo Clinic Cancer Center - Phoenix
- Arizona Oncology - Scottsdale
- University Medical Center - Tucson
Colorado
- Children's Hospital Colorado - Aurora
- US Oncology - Denver - Denver
Alabama
- Children's Hospital of Alabama - Birmingham
Arkansas
- University of Arkansas for Medical Services - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,206 participants |
| Start Date | 2007-12 |
| Est. Completion | 2016-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00628498
The ClinicalTrials.gov registry entry for NCT00628498 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,206 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatic Veno-Occlusive Disease appearing as the primary indexed condition, and to 1 intervention - of which Defibrotide is the first listed.
NCT00628498 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT00628498 about?
NCT00628498 is a clinical study titled "Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study". Single arm, open-label study to provide Defibrotide to patients diagnosed with VOD. Defibrotide is no longer available though the Emergency Use IND mechanism (also known as compassionate use, or single patient named use). This protocol is the only mechanism by which Defibrotide can be made available...
What is the current status of trial NCT00628498?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,206 participants. The study started on 2007-12. Estimated completion is 2016-09.
What conditions does trial NCT00628498 study?
This clinical trial studies the following conditions: Hepatic Veno-Occlusive Disease.
What interventions are being tested in trial NCT00628498?
The interventions under investigation include: Defibrotide (DRUG).
Who is sponsoring clinical trial NCT00628498?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00628498 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.